APGE · NASDAQ · STOCK
Apogee Therapeutics, Inc.
$134.70
52W $34.58 – $134.88
63/100
$8.33B
-31.0
0.33
Is APGE Bullish or Bearish?
Bullish.
Innellis AI committee rates Apogee Therapeutics, Inc. (APGE) Buy with a composite score of 63/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- RSI at 75 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 90 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
63/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 26%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -32.6% -- cheap may mean cheap for a reason
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 75 is in overbought territory
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
75.4
Overbought
MACD Histogram
-1.131
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$134.46
Above
EMA 21
$132.65
Above
EMA 50
$121.96
Above
EMA 200
$89.90
Above
Fundamental Analysis
Valuation
33
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-31.0×
P/B Ratio
8.51×
PEG Ratio
6.55
Dividend Yield
0.00%
52W High
$134.88
52W Low
$34.58
Quality & Growth
ROE
-2830.5%
ROA
-2730.1%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -31.0 (inexpensive relative to a 15-40x range); Price-to-book of 8.5x; PEG ratio of 6.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -28.3%; Return on assets of -27.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 26.44 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-3.23); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full APGE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →